RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > 8 > CDER Seeks Site Visit Proposals for FY 2019 Learning Program

CDER Seeks Site Visit Proposals for FY 2019 Learning Program

Posted 23 August 2018 | By Ana Mulero 

CDER Seeks Site Visit Proposals for FY 2019 Learning Program

The US Food and Drug Administration called on pharmaceutical companies on Thursday to submit site visit proposals for FY 2019 as part of a voluntary learning program for agency staff.
The Staff Experiential Learning Site Visit (ELSV) Program—first announced in 2016—aims to provide staff at the Office of Pharmaceutical Quality within FDA’s Center for Drug Evaluation and Research (CDER) new learning opportunities with in-person visits to drug manufacturing sites.
In a Twitter thread on Thursday, FDA Commissioner Scott Gottlieb highlighted the program's objectives. The current four main areas of interest to FDA staff include drug products; active pharmaceutical ingredients manufactured by chemical synthesis, fermentation or biotechnology; design, development, manufacturing and controls; and emerging technologies. Specific topics include modified and immediate release formulations, drug-device combination products, continuous manufacturing and 3D-printing, according to Thursday's notice.

FDA’s notice also details the information that should be provided in each ELSV proposal, including proposed agendas on learning objectives and dates for each agency site visit. 

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.